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ABSTRACT  
Background: The International Depression/anxiety Epidemiological Study (TIDES) in the 
UK aimed to establish: (i) the prevalence of anxiety and depression amongst people with CF 
compared to a normative sample, (ii) the association between mood, demographic and 
clinical variables and, (iii) guidance for specialist-referral decision-making.   
 
Methods: Patients (≥12 years) completed the Hospital Anxiety and Depression Scale 
(HADS). CF-HADS scores, expressed as percentiles, were compared with a normative 
sample. Multiple-regression analysis explored associations between demographic, clinical 
and mood variables. 
 
Results: Thirty-nine CF Centres recruited 2065 patients.  Adults with CF were similar in 
terms of anxiety and depression to the general population.  Adolescents with CF were less 
anxious and depressed. For adult patients, older age, unemployment for health reasons and 
poor lung function were associated with disordered mood.  Gender-specific CF-percentile 
scores were calculated.  
 
Conclusion: Surveillance, with attention to gender and risk factors is advocated.  This work 
provides unique benchmark scores to aid referral decision-making. 
 
Key words; anxiety, depression, HADS, cystic fibrosis, prevalence, management 
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Background 
Advances in the diagnosis and treatment of cystic fibrosis (CF) have led to dramatic 
improvements in prognosis [1,2].  However, arduous treatment regimens [3], considerable 
morbidity and early mortality [1] impact on psychological health which remains a critical 
target for assessment and intervention. 
 
There is a complex relationship between psychological and physical health [4].  Those with 
respiratory disease have an increased risk for co-morbid anxiety and depression [5-7], with 
routine assessment recommended [8].  However, the findings in CF are inconsistent, as 
there are difficulties interpreting and comparing results across studies because of different 
sampling approaches, measurement instruments and a lack of consensus on clinical cut-off 
scores.  Single-centre reports of adult patients cite depression rates of 17-30%, linking 
depression with worse adherence, poorer lung-function and quality of life (QoL) [9-11].  
Lower and elevated rates of depression have been reported in children, adolescents and 
young adults who have CF compared with healthy controls [12,13].  Normal [12-14] and 
elevated levels of anxiety [15,16] have been reported in adult and adolescent patients. 
 
To address the limitations of previous studies The International Depression/anxiety 
Epidemiology Study (TIDES) aimed to conduct rigorous evaluation of depression and anxiety 
in CF patients and parent-caregivers in eight European countries and the US.  Although 
some preliminary TIDES findings have been presented in abstract form, to date only one 
national patient data-set has been published (TIDES-Germany).  In this study, patients were 
no more or less depressed that the general population, however, adults with CF had greater 
elevated symptoms of anxiety than healthy controls.  Younger patients reported fewer 
symptoms of both depression and anxiety than older ones [17].   
 
This paper presents TIDES-UK patient data, which aimed to estimate; (i) prevalence of 
depression and anxiety amongst adolescents and adults with CF in the UK in comparison to 
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a normative, adult UK sample, (ii) associations between mood, demographic and clinical 
variables and, (iii) provide guidance for specialist referral decision-making.  Rates of 
depression and anxiety were expected to be higher in those with CF than in the general 
population and elevated symptoms were expected to be associated with worse health status. 
 
 
Materials and methods 
Study design 
A cross-sectional study involving paediatric and adult UK CF centres was undertaken.  
National Research Ethics Service approval was granted (NRES 07/Q1205) with site-specific 
approval being obtained from local Research and Development units.  All participants 
provided written consent.  Parental consent and child assent were given for those under 16 
years.  Final consent was taken in April 2012.  
 
Subjects and procedure 
All patients (≥12 years) except for transplant-recipients were asked to participate in the study 
during routine out-patient appointments between October 2009 and April 2012.  
Demographic, clinical, and mood variables were collected and the Hospital Anxiety and 
Depression Scale (HADS) [18] was completed immediately prior to consultations.  The 
HADS was scored within a week with referral pathways in place (referral to CF psychosocial 
professional or liaison with external mental health services).   
 
Measures 
Demographic and clinical variables 
Demographic and clinical data were obtained from participants and verified by medical 
records where appropriate.  Not all clinics collected every variable but when possible, the 
following data were obtained: age, gender, height, weight, FEV1% predicted, education-level, 
employment status, diabetes, current IV-antibiotics, nutritional supplements, enteral tube 
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feeds, intravenous access device and whether the person was diagnosed with diabetes, 
haemoptysis or pneumothorax in the past six months.  Whether the participant was listed for 
transplant, had a current prescription for anti-depressants or anxiolytics or was engaged in 
counselling for depression or anxiety, were documented. 
 
Hospital Anxiety and Depression Scale (HADS) 
The HADS was indentified as the most appropriate TIDES measure because of its extensive 
reliability and validity data [19], good sensitivity and specificity [20] and international 
translations.  It is a 14-item (7 depression, 7 anxiety), self-report scale that evaluates and 
quantifies anxiety and depression in hospital settings without somatic items.  Respondents 
consider how they have been feeling over the past 7 days and answer on 4-point Likert 
scaling (scored ‘0’ - ‘3’), yielding a total anxiety or depression score of between 0 and 21.  
Depression and anxiety are categorised according to published thresholds [21] (‘none’: raw 
scores <7; ‘mild’: 8-10; ‘moderate’: 11-15; ‘severe’: ≥16) however, there is little agreement 
about the clinical value of these which makes it difficult to interpret data and establish 
referral pathways for specialist assessment [22]. 
 
An alternative approach of using a HADS centile-structure was proposed in a large study of 
non-clinical UK adults (978 women, 810 men) in community settings.  This sample was 
deemed representative of the UK population in terms of age, gender and occupational status 
[23].  Using these normative data, gender-specific tables converted raw HADS scores to 
percentiles which establish the comparative scarcity of a person’s depression or anxiety 
score and augment management decisions based on comparative severity. 
 
Statistical analysis 
To provide contextual information about the estimated prevalence of depression and anxiety 
in CF, the categorised prevalence of anxiety and depression (‘none’, ‘mild’, ‘moderate’ or 
‘severe’) was compared between the UK normative adult sample and the adult CF sample, 
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and between the latter and the adolescent CF sample, using chi-squared or Fisher’s exact 
tests (there are no UK normative data for adolescents) and independent samples t-tests.  
Graphical comparisons were made between samples by comparing the percentile plots of 
the empirical cumulative distribution functions. 
 
Regression analysis was used to explore the influence of demographic and clinical variables 
on depression and anxiety.  Preliminary regressions using the total depression and anxiety 
scores showed highly skewed residuals and heterogeneity in the residual variance.  
Therefore, these scores were transformed firstly to the percentile of the empirical cumulative 
distribution of the observed score and secondly, using the logistic transformation.  The 
empirical cumulative distribution function used was the one appropriate to the gender and 
the set of data, CF adult or CF adolescent.  These transformations achieved homogeneity of 
variance and satisfactory approximation to the normal distribution, thus, supporting valid P-
values with which to assess significant associations. 
 
The following strategy was used to identify variables associated with depression and anxiety. 
Variables were divided into two groups for both adults and adolescents; the core group of 
variables which were available for most individuals and the secondary group of variables, 
which were available for a reduced subset of individuals (not all variables were collected in 
every clinic).  Regressions were undertaken that included both core and secondary variables 
using the reduced sample size of individuals who had all variables available.  These 
regressions tested the associations between depression and anxiety with the secondary 
variables.  Regressions were then repeated using only core variables, but utilising the larger 
sample size.  These regressions tested the associations between depression and anxiety 
with the core variables. 
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RESULTS 
Study population 
The 39 study sites (25 adult, 14 paediatric) included 23/48 CF centres registered with the UK 
CF Trust and 16 regional clinics.  The smallest site had 8 patients; the largest, 530.  Twenty-
three sites (59%) recruited >70% of their clinic population, with a further 6 (15%) recruiting 
>60%.  A total of 1780 adults and 285 adolescents with CF were included in the study (total 
n=2065).  This represented 45.2% of the total UK adult CF population and 18.3% of 
adolescents (12-17 years), based on UK CF Trust Registry data [1], having similar age and 
FEV1 distributions and median BMI.  Demographic and clinical characteristics are shown in 
Table 1. 
 
Direct or indirect access to a clinical psychologist was available in 28 of the 39 (72%) 
participating sites.  Of the 23 participating major centres, integrated clinical psychology posts 
were established in 18 (78%) with indirect access via a generic hospital clinical psychologist 
being available in a further 3 (13%).  In the 16 participating regional clinics whilst there was 
no direct access, support was available indirectly in 7 (44%), via network centres or 
community services.  
 
Internal reliability of the HADS was robust with satisfactory Cronbach alpha coefficients for 
depression (0.82 and 0.72) and anxiety (0.80 and 0.85) for adults and adolescents, 
respectively. 
 
Estimated prevalence of depression and anxiety 
Table 2 shows the estimated prevalence of depression and anxiety in men and women with 
CF, adolescent boys and girls with CF and UK normative data together with mean scores.  
 
In terms of prevalence, men with CF were significantly more depressed (Χ2 = 10.4; P=0.014) 
and anxious (Χ2 = 24.3; P<0.001) than men from the general population, but the differences 
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were small. However, although mean depression score was lower (3.4 for men with CF; 3.6 
for UK men) and was not significantly different (P=0.200), mean anxiety score was the same 
for both groups at 5.7.  Adolescent boys with CF were less depressed (Χ2 = 19.0; P<0.001) 
and anxious (Χ2 = 12.5; P=0.006) than adult CF men. Mean depression and anxiety scores 
for adolescent boys with CF were significantly lower than that for men with CF (depression 
1.9 P<0.001; anxiety 4.3 P<0.001).  
 
Women with CF were not significantly different to adult women from the general population 
for both depression (Χ2 = 2.38; P=0.50) and anxiety (Χ2 = 1.03; P=0.79).  In fact mean 
depression score was significantly lower for CF women at 3.4 compared to 4.0 for UK adult 
women (P<0.001) and mean anxiety score was also lower but not significantly so (6.6 versus 
6.8, P=0.311).  Adolescent girls with CF were not significantly different to women with CF for 
both depression (Χ2 = 5.10; P=0.15) and anxiety (Χ2 = 5.53; P=0.14) but this is likely the 
result of a small sample size for adolescents, since the P-values are close to 15%.  Mean 
depression score was significantly lower at 2.4 for girls with CF compared to 3.4 for women 
with CF (P<0.001).  Mean anxiety score was significantly lower at 5.7 for girls with CF 
compared to 6.6 for women with CF (P=0.011). 
 
In summary, adults with CF were similar in terms of depression and anxiety to the general 
population, any differences being small.  However, adolescent boys and girls with CF were 
less depressed and anxious than their adult counterparts.  This is demonstrated graphically 
in Figures 1 and 2. 
 
Associations between mood, demographic and clinical variables 
Adults with CF 
The core variables comprised: BMI, FEV1% predicted, age, education, employment status, 
routine/unwell visit and current use of intravenous antibiotics.  Secondary variables were: 
diabetic condition, development of diabetes and haemoptysis in previous 6 months, listed for 
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transplant, nutritional supplements, enteral tube feeding and a port-a-cath in situ.  
Pneumothorax was excluded because only 4 individuals had experienced this in the past 6 
months. 
 
Depression: In the regressions with core and secondary variables (292 men, 261 women), 
the percentage variance accounted for (R2) was 21% for men and 27.5% for women.  For 
men, no secondary variable showed any association with level of depression.  For women, 
only recent haemoptysis was associated with increased depression.  In the regressions with 
only core variables (885 men, 811 women), R2 was 15.5% for men and 15.9% for women; 
again a poor level of explanation.  Generally, for men and women, increasing age, not 
working due to health reasons, decreasing FEV1% predicted and a clinic visit whilst unwell 
were associated with increased depression scores.  BMI, level of educational attainment and 
current IVs showed no association with depression.  
 
Anxiety: In the regressions with core and secondary variables (292 men, 261 women), R2 
was 8.7% for men and 16.6% for women.  For men, no secondary variable was associated 
with level of anxiety.  For women, only recent haemoptysis predicted higher levels of anxiety.  
In the regressions with only core variables (885 men, 811 women) R2 was 4.4% for men and 
7.0% for women; a poor level of explanation.  For both men and women, age group and 
employment status were both significant.  Generally, increasing age predicted increased 
anxiety scores.  Typically, those in full-time employment reported the least anxiety, whereas 
those not working due to health reasons reported the highest levels.  For women, an ‘unwell’ 
visit was associated with heightened anxiety and the use of IVs was related to lower anxiety. 
FEV1% predicted, BMI and level of educational attainment showed no association with 
anxiety. 
 
For the demographic and clinical variables that demonstrated a statistically significant 
association with depression or anxiety, Table 3 shows unadjusted mean values of 
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depression and anxiety together with the P-values from the regressions.  The means are for 
the individuals who were included in the appropriate regression which generated the P-
value.  Unadjusted means are given because adjusted values would be difficult to interpret 
following the data transformations.  Although some variables were shown to be statistically 
significant, the means in Table 3 indicate that they were not always clinically relevant.  
 
Adolescents with CF 
Core variables included: BMI, FEV1% predicted, routine/unwell visit and current intravenous 
antibiotics.  Secondary variables comprised: diabetes, nutritional supplements, enteral tube 
feeding and a port-a-cath in situ.  Other variables were excluded because too few individuals 
were involved.  In the regression analyses of core and secondary variables, 71 boys and 77 
girls were included; R2 was 4.6% for boys and 24.3% for girls for depression and 8.4% for 
boys and 11.8% for girls for anxiety.  For both boys and girls, no secondary variable showed 
any association with anxiety.  For boys, none of the secondary variables showed any 
association with depression, but for girls, a port-a-cath in situ was associated with elevated 
levels of depression and diabetes with reduced depression.  Table 3 also includes 
unadjusted means and P-values for diabetes and port-a-cath in situ for depression in girls.  
In regressions with core variables, 114 boys and 139 girls were included and R2 was 3.1% of 
boys and 4.6% of girls for depression and 1.6% of boys and 4.4% of girls for anxiety; a 
negligible level of explanation.  For both boys and girls, no core variable showed any 
association with anxiety. 
 
Specialist referral threshold scores 
Table 4 shows the depression and anxiety scores for referral based on the top 20%, 10%, 
5% and 1% of patients with CF.  If referral decisions are based on raw HADS scores (e.g., a 
score of 11 for ‘moderate’ anxiety) then men would be referred if they were in the top 10% of 
the anxiety distribution for men with CF.  Women would be referred in the top 20% of the 
anxiety distribution for CF women.  For boys with CF, referral would be only in the top 5% 
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and for girls in the top 10%.  Therefore, clinicians may want to refer patients for depression 
and anxiety based on the same top percentile for all groups.  If referral for anxiety was based 
on a score placing a patient in the top 5% of the anxiety distribution, then men with CF would 
be referred at score 13, women at score 14, boys at 10 and girls at 12.  For depression the 
analogous scores are 10, 10, 6 and 8 respectively. 
 
DISCUSSION 
TIDES-UK is the first study to investigate rates of depression and anxiety in a large, multi-
centred, UK sample of people with CF.  Adults with CF had a similar estimated prevalence of 
depression and anxiety as the general population.  This was contrary to expectations [24] 
and cannot be explained by the decade time-difference between the normative and CF 
samples, as more recent normative data established virtually identical means and standard 
deviations [25].  Moreover, the estimated prevalence of depression reported by TIDES-
Germany was also similar to that of a normative sample [17], albeit that estimated UK 
anxiety was higher than that reported in Germany, which in turn was higher than the 
respective normative group.  Comparison with single-centre studies or narrative reviews 
which report variable rates of depression and anxiety are not particularly useful given the 
methodological limitations and varying results of such reports. 
 
Adolescents with CF were less depressed and anxious than their adult counterparts, with 
elevated depression scores being minimal in adolescent boys.  Adherence problems in this 
group are frequently noted and together with a decline in lung-function between the ages of 
12 and 16 years [1], there remains a clinically compelling case for maintaining close 
observation.   
 
The importance of evaluating and attending to, patients' and relatives’ emotional well-being 
is gaining worldwide support.  In the UK psychological provision is well-established as part of 
CF management, with centres mandated to provide integrated clinical psychological care as 
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part of the service specification [26].  It is plausible that low rates of depression and anxiety 
were detected in this study as a result of there being direct or indirect access to a clinical 
psychologist in 91% of participating major centres and 44% of regional clinics, (72% access 
overall). 
 
Surveillance with special attention to gender and the risk factors FEV1% predicted, age and 
work status, is advocated given that 'moderate/severe’ depression was reported by 3.1% of 
men and 4.6% of women and ‘moderate/severe’ anxiety was reported by 11.5% of CF men 
and 17.2% of CF women.  Poor lung-function was associated with elevated depression 
scores in adults, a finding reported by several studies [8,9,17].  The combination of 
depression and poor lung-function had a greater adverse effect on QoL than poor lung-
function alone [10].  Older-age and not working due to health reasons were also associated 
with higher rates of depressive and anxiety symptoms.  These results highlight important 
psychosocial benefits of living with CF and being in full-time employment [27,28] and a 
timely reminder that the new era of CF care with mutation-specific treatments, affords 
greater confidence in psychologically preparing adolescents for the full opportunities of adult 
life.  Additionally, for adult females, psychopathology was associated with haemoptysis and 
attending clinic when unwell (although lower levels of depression were reported whilst on 
intravenous [IV] treatment).  In adolescent girls, having a port-a-cath in situ was associated 
with higher depression scores and consistent with poor QoL reporting [29]. 
 
The HADS is a practical tool for estimating depression and anxiety.  It is reliable and valid 
and remains popular in clinical settings due to its ease of use and the weaknesses of other 
measures.  Whether or not the HADS is the most appropriate assessment tool in CF remains 
to be evaluated.  It does not represent the multi-dimensional nature of depression and omits 
somatic items which can be linked to depression or anxiety but does have advantages over 
other scales (e.g., the CES-D confounds psychological and somatic symptoms of CF; the 
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PHQ-9 includes an item on suicidal ideation requiring resource-intensive administration, 
which is considered in the TIDES-UK pilot data [30]).  However, such considerations are 
tempered by questions over the validity of utilising case-finding or screening questionnaires 
alone.  Systematic review of 16 studies with 7576 patients, suggests that the adoption of 
screening strategies using standardised questionnaires without organisational 
enhancements are not justified [31].  
 
TIDES-UK data present a unique opportunity to establish meaningful management of HADS 
thresholds and clinical responses via the conversion of raw scores into gender-specific, CF-
centile scores, which determine who should be kept under a watchful eye, undergo further 
assessment and be referred for psychosocial and/or mental health intervention (Table 4).  
Previously this has been a contentious issue.  In the original paper [18] of the 18 patients in 
the ‘borderline’ range for depression (8+) only 3 presented as definite cases.  Of the 20 
patients in the same category for anxiety (again 8+), only 1 presented as a definite case.  It 
is wrong to consider these as diagnostic of clinical depression and/or anxiety.  Instead it is 
vital that elevated scores are followed by clinical assessment and diagnosis, with referral for 
psychological intervention when necessary.  In accordance with clinical psychology opinion 
for hospitalised patients, a cut-off at the 90th percentile on the HADS depression scale was 
deemed the appropriate point for referral for clinical interview with a psychologist [32]. 
Similarly, in a community sample evaluating the longitudinal effect of anxiety and depression 
on blood pressure, the 90th percentile of the HADS were also estimated to be the appropriate 
clinical cut-off points [33].   We advocate ‘watchful waiting’ at the 80th centile, ‘follow-up with 
clinical discussion in the CF team’ at the 90th centile, ‘referral to mental health for diagnostic 
assessment and intervention’ at the 95th centile and ‘emergency referral’ at the 99th centile. 
 
Whilst TIDES-UK was a large study in a comparatively rare disease, with excellent clinical 
representation of the UK CF population, some sampling bias may still have occurred.   There 
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was a lower response rate for adolescents and this should temper the interpretation of these 
data.  Refusal rates were unavailable and out-patient clinic recruitment possibly excluded 
poor/non-attendees.  The reasons for refusal/poor attendance remain unknown but may 
have been influenced by psychological symptoms, leading to an under-estimate of 
psychopathology.  The study was cross-sectional but provides robust prevalence estimates, 
risk factors and critically, threshold referral information.  We await longitudinal follow-up to 
evaluate the trajectory and predictors of depression and anxiety over time.   
 
Conclusions 
Adults with CF in the UK have similar rates of depression and anxiety to the general 
population.  Adolescent patients were less anxious and depressed than their adult 
counterparts.  Older age, not working due to health and poor lung-function were associated 
with disordered mood.  With no consensus on thresholds for specialist assessment or 
onward referral, converted gender-specific CF percentiles provide unique benchmark profiles 
that aid clinical management in deciding which patients to ‘watch and wait’, further assess  
or refer on. 
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Table 1. Demographic and clinical characteristics of the CF participants in the HADS study.  
 Adults (18 years and older) Adolescents (12 to 17 years) 
 
Sample size 
Men 
929 
Women 
851 
All 
1780 
Boys 
136 
Girls 
149 
All 
285 
 Age  12-17 
          18-23 
          24-29 
          30-39 
          40-49 
          50-59 
          60+ 
 
326(35.1) 
268(28.8) 
209(22.5) 
99(10.7) 
17(1.8) 
10(1.1) 
 
315(37.1) 
243(28.6) 
177(20.8) 
79(9.3) 
23(2.7) 
13(1.5) 
 
641(36.0) 
511(28.7) 
386(21.7) 
178(10.0) 
40(2.2) 
23(1.3) 
 136(100)  149(100) 285(100) 
BMI (kg m-2)      
     Mean (SD)    
     Range 
 
22.8 (3.7) 12.5-
42.8 
 
21.9 (3.7) 
12.7-39.7 
 
22.4 (3.7) 
12.5-42.8 
 
19.9 (3.5) 
13.4-36.3 
 
20.2 (3.1) 
13.6-33.2 
 
20.1 (3.3) 
13.4-36.3 
FEV1%predicted 
     Mean (SD)    
     Range 
 
61.6  (24.8) 
12-135 
 
60.1 (23.4) 
15.132 
 
60.9 (24.1) 
12-135 
 
80.0 (18.7) 
29-129 
 
73.6 (21.3) 
18-122 
 
76.6 (20.3) 
18-129 
Education 
     No formal qualns 
     O levels/GCSE 
    A levels /equivalent 
University degree 
     Postgrad. studies 
     Professional qualns 
 
97(10.6) 
267(29.1) 
236(25.7) 
184(20.0) 
40(4.4) 
95(10.3) 
 
68(8.1) 
257(30.5) 
240(28.4) 
137(16.2) 
48(5.7) 
94(11.1) 
 
165(9.4) 
524(29.7) 
476(27.0) 
321(18.2) 
88(5.0) 
189(10.7) 
   
Employment 
    Working full-time 
    Working part-time 
    Not working - health    
    Not working -  other 
 
378(41.1) 
158(17.2) 
211(23.0) 
      172(18.7) 
 
237(28.3) 
205(24.5) 
209(25.0) 
186(22.2) 
 
615(35.0) 
363(20.7) 
420(23.9) 
358(20.4) 
   
Type of visit 
    Routine 
    Unwell 
 
856(92.6) 
68(7.4) 
 
773(91.7) 
70(8.3) 
 
1629(92.2) 
138(7.8) 
 
133(97.8) 
3(2.2) 
 
141(95.2) 
7(4.7) 
 
274(96.5) 
10(3.5) 
Diabetic 
    No 
    Yes 
 
225(75.8) 
72(24.2) 
 
186(69.4) 
82(30.6) 
 
411(72.7) 
154(27.3) 
 
78(91.8) 
7(8.2) 
 
69(85.2) 
12(14.8) 
 
147(88.6) 
19(11.4) 
Diabetic in last 6m 
    No 
    Yes 
 
885(95.9) 
38(4.1) 
 
804(94.9) 
43(5.1) 
 
1689(95.4) 
81(4.6) 
 
131(98.5) 
2(1.5) 
 
140(96.6) 
5(3.4) 
 
271(97.5) 
7(2.5) 
Hemoptysis in last 6m 
    No 
    Yes 
 
225(75.8) 
72(24.2) 
 
196(73.1) 
72(26.9) 
 
421(74.5) 
144(25.5) 
 
84(98.8) 
1(1.2) 
 
75(92.6) 
6(7.4) 
 
159(95.8) 
7(4.2) 
On IV antibiotics 
    No 
    Yes 
 
883(95.6) 
41(4.4) 
 
772(91.7) 
70(8.3) 
 
1655(93.7) 
111(6.3) 
 
126(94.7) 
7(5.3) 
 
133(91.7) 
12(8.3) 
 
259(93.2) 
19(6.8) 
Listed for transplant 
    No 
    Yes 
 
903(97.7) 
21(2.3) 
 
821(97.5) 
21(2.5) 
 
1724(97.6) 
42(2.4) 
 
133(100.0) 
0(0.0) 
 
144(99.3) 
1(0.7) 
 
277(99.6) 
1(0.4) 
Nutritional suppl. 
    No 
    Yes 
 
166(55.9) 
131(44.1) 
 
172(64.2) 
96(35.8) 
 
338(59.8) 
227(40.2) 
 
53(62.4) 
32(37.6) 
 
57(70.4) 
24(29.6) 
 
110(66.3) 
56(33.7) 
Enteral tube feeds 
    No 
    Yes 
 
277(93.3) 
20(6.7) 
 
253(94.4) 
15(5.6) 
 
530(93.8) 
35(6.2) 
 
76(89.4) 
9(10.6) 
 
67(82.7) 
14(17.3) 
 
143(86.1) 
23(13.9) 
Portacath insitu 
    No 
    Yes 
 
239(80.7) 
57(19.3) 
 
178(66.4) 
90(33.6) 
 
417(73.9) 
147(26.1) 
 
61(71.8) 
24(28.2) 
 
38(46.9) 
43(53.1) 
 
99(59.6) 
67(40.4) 
Taking antidepressant  
    No 
    Yes 
 
864(93.5) 
60(6.5) 
 
745(88.6) 
96(11.4) 
 
1609(91.2) 
156(8.8) 
 
133(100.0) 
0(0.0) 
 
141(97.9) 
3(2.1) 
 
274(98.9) 
3(1.1) 
Counselling for mood 
    No 
    Yes 
 
862(93.3) 
62(6.7) 
 
771(91.7) 
70(8.3) 
 
1633(92.5) 
132(7.5) 
 
130(97.7) 
3(2.3) 
 
133(92.4) 
11(7.6) 
 
263(94.9) 
14(5.1) 
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Table 2. Percentages of samples in each diagnosis group for HADS anxiety and depression score, 
means and standard deviations (SD). 
 Men   Women   
 Normative  
adults 
CF  
adults 
CF   
boys 
Normative  
adults 
CF  
adults 
CF   
girls 
Sample size 810 929 119 978 850 144 
Anxiety score       
None(0-7)  % 73.0 69.9 84.9 61.0 61.5 70.1 
Mild (8-10) % 18.0 18.6 10.1 23.0 21.3 14.6 
Moderate (11-15) % 8.0 9.5 5.0 13.0 14.0 13.9 
Severe(16-21) % 
P-value 
Mean 
SD 
1.0 
 
             5.7 
             3.7 
2.0 
<0.001 
     5.7 
     3.9 
0.0 
0.006 
        4.3 
        3.2 
3.0 
 
6.8 
4.1 
3.2 
0.794 
6.6 
4.3 
1.4 
0.137 
5.7 
3.8 
P-value  1.00 <0.001  0.311 0.011 
Depression score       
None(0-7)  % 91.0 86.9 99.2 86.0 88.1 94.4 
Mild (8-10) % 6.0 10.0 0.8 9.0 7.3 2.8 
Moderate (11-15) % 2.3 2.8 0.0 4.0 3.9 2.8 
Severe(16-21) % 
P-value 
Mean 
SD 
0.7 
 
3.6 
3.2 
0.3 
0.014 
3.4 
3.3 
0.0 
<0.001 
1.9 
2.0 
1.0 
 
4.0 
3.6 
0.7 
0.498 
3.4 
3.4 
0.0 
0.146 
2.4 
2.9 
P-value  0.200 <0.001  <0.001 <0.001 
Based on Snaith and Zigmond (1994) recommended cut-off scores (mild: raw scores between 8 and 10; moderate:  
11-15; severe: 16 and above).  Normative UK adults from Crawford et al 2001. 
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Table 3. Unadjusted mean values and standard errors (SE) of significant predictors of anxiety and 
depression scores for adults and adolescents with cystic fibrosis together with p-values from 
regression analyses. 
 Anxiety Depression 
 Men  p-value Women  p-value Men  p-value Women  p-value 
Sample size 885  811  885  811  
Age         
18-23 5.0(0.2)  6.1(0.3)  2.7(0.2)  2.9(0.2)  
24-29 5.7(0.2) 0.041 6.9(0.3) 0.048 3.1(0.2) 0.078 3.4(0.2) 0.007 
30-39 6.1(0.3) 0.004 6.6(0.3) 0.390 3.7(0.2) <0.001 3.5(0.3) 0.151 
40-49 6.5(0.4) 0.004 6.9(0.5) 0.504 4.7(0.4) <0.001 3.3(0.1) 0.198 
50+ 5.5(0.9) 0.909 6.5(0.2) 0.061 4.4(0.8) 0.066 4.7(0.6) 0.005 
Employment         
Full-time 5.2(0.2)  5.6(0.3)  2.5(0.1)  2.3(0.2)  
Part-time 6.0(0.3) 0.010 6.5(0.3) 0.016 3.2(0.2) 0.008 2.8(0.2) 0.104 
Not working - health 6.6(0.3) <0.001 8.0(0.3) <0.001 5.1(0.3) <0.001 5.2(0.3) <0.001 
Not working - other 5.2(0.3) 0.278 6.3(0.3) 0.024 3.0(0.3) 0.002 3.1(0.2) 0.006 
On IV antibiotics         
No   6.6(0.2)      
Yes   6.3(0.5) 0.024     
Type of visit         
Routine   6.5(0.2)  3.2(0.1)  3.2(0.1)  
Unwell   7.9(0.6) 0.010 4.7(0.4) 0.035 5.0(0.5) <0.001 
FEV1%predicted         
Normal    (>100%)     2.3(0.4)  2.4(0.4)  
Mild (70-100%)     2.7(0.2) 0.399 2.5(0.2) 0.612 
Moderate   (40-69%)     3.3(0.2) 0.283 3.6(0.2) 0.038 
Severe      (<40%)     4.5(0.2) 0.019 4.1(0.3) 0.036 
Sample size   261    261  
Hemoptysis          
in last 6m No   6.3(0.3)    2.8(0.2)  
Yes   8.8(0.6) 0.001   5.5(0.5) <0.001 
        
Girls 
 
p-value 
Sample size       77  
Diabetes         
No       2.8(0.4)  
Yes       1.8(0.8) 0.027 
Portacath in situ         
No       1.5(0.3)  
Yes       3.6(0.6) 0.010 
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Table 4.  Anxiety and depression scores for referral based on position in top percentage for 
patients with CF.  
       Anxiety          Depression 
 20% 10% 5% 1% 20% 10% 5% 1% 
Men:         
CF adults 9-10 11-12 13-16 17-21 6-7 8-9 10-13 14-21 
CF adolescents 7-8 9 10-12 13-21 4 5 6 7-21 
Women:         
CF adults  10-12 13 14-17 18-21 6-7 8-9 10-14 15-21 
CF adolescents 10 11 12-14 15-21 4-5 6-7 8-11 12-21 
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Figure Legends: 
Figure 1: Percentile plots for anxiety scores for (a) adult men with CF (solid line) and 
normative men (broken line)  (b) adult women with CF (solid line) and normative women 
(broken line) (c) adult men with CF (solid line) and boys with CF (broken line) and (d) adult 
women with CF (solid line) and girls with CF (broken line). Normative UK adult data from 
[21]. 
Figure 2: Percentile plots for depression scores for (a) adult men with CF (solid line) and 
normative men (broken line)  (b) adult women with CF (solid line) and normative women 
(broken line) (c) adult men with CF (solid line) and boys with CF (broken line) and (d) adult 
women with CF (solid line) and girls with CF (broken line). Normative UK adult data from 
[21]. 
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